Patents by Inventor Iok Chan Ng
Iok Chan Ng has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240082245Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: November 3, 2023Publication date: March 14, 2024Inventors: Christine Collins, Bo Fu, Abhishek Gulati, Jens Kort, Matthew Kosloski, Yang Lei, Chih-Wei Lin, Ran Liu, Federico Mensa, Iok Chan NG, Tami Pilot-Matias, David Pugatch, Nancy S. Shulman, Roger Trinh, Rolando M. Viani, Stanley Wang, Zhenzhen Zhang
-
Patent number: 11639390Abstract: The present disclosure provides anti-?4?7 antibodies that bind human ?4?7, their methods of making, and their uses to treat patients with HIV infection.Type: GrantFiled: July 16, 2021Date of Patent: May 2, 2023Assignee: AbbVie Inc.Inventors: Jing Min, Teresa (Iok-Chan) Ng, Lorenzo Benatuil, Jacqueline Bixby, Tatyana Dekhtyar, Feng Dong, Axel Hernandez, Jr., Preethi Krishnan, Liangjun Lu, Federico Mensa, Renee Miller, Gautam Sahu
-
Publication number: 20220017624Abstract: The present disclosure provides anti-?4?7 antibodies that bind human ?4?7, their methods of making, and their uses to treat patients with HIV infection.Type: ApplicationFiled: July 16, 2021Publication date: January 20, 2022Inventors: Jing Min, Teresa (Iok-Chan) Ng, Lorenzo Benatuil, Jacqueline Bixby, Tatyana Dekhtyar, Feng Dong, Axel Hernandez, Jr., Preethi Krishnan, Liangjun Lu, Federico Mensa, Renee Miller, Gautam Sahu
-
Publication number: 20200368229Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: August 2, 2017Publication date: November 26, 2020Applicant: AbbVie Inc.Inventors: Christine Collins, Bo Fu, Abhishek Gulati, Jens Kort, Matthew Kosloski, Yang Lei, Chih-Wei Lin, Ran Liu, Federico Mensa, Iok Chan Ng, Tami Pilot-Matias, David Pugatch, Nancy S. Shulman, Roger Trinh, Rolando M. Viani, Stanley Wang, Zhenzhen Zhang
-
Publication number: 20200330460Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: August 30, 2018Publication date: October 22, 2020Applicant: AbbVie Inc.Inventors: Christine Collins, Emily O. Dumas, Bo Fu, Abhishek Gulati, Yiran Bonnie Hu, Jens Kort, Matthew Kosloski, Preethi Krishnan, Yang Lei, Chih-Wei Lin, Ran Liu, Frederico Mensa, Iok Chan Ng, Tami Pilot-Matias, David Pugatch, Susan Rhee, Nancy S. Shulman, Roger Trinh, Rolando M. Viani, Stanley Wang, Zhenzhan Zhang
-
Publication number: 20200222397Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 16 weeks, alternatively no more than 12 weeks, or alternatively no more than 8 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 16, 12, or 8 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: July 20, 2018Publication date: July 16, 2020Applicant: AbbVie Inc.Inventors: Christine Collins, Bo Fu, Abhishek Gulati, Jens Kort, Matthew Kosloski, Yang Lei, Chih-Wei Lin, Ran Liu, Federico Mensa, Iok Chan Ng, Tami Pilot-Matias, David Pugatch, Nancy S. Shulman, Roger Trinh, Rolando M. Viani, Stanley Wang, Zhenzhen Zhang
-
Patent number: 10233179Abstract: This disclosure relates to: (a) compounds and salts thereof that, inter alia, inhibit RSV infection and/or replication; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions.Type: GrantFiled: April 22, 2014Date of Patent: March 19, 2019Assignee: Abbvie Inc.Inventors: Iok Chan Ng, M-akhteruzzaman Molla, Tami J. Pilot-Matias, Anil Vasudevan, Tatyana Dekhtyar, Artour Gomtsian, Kathy Sarris, Ana Aguirre, Mikhail Chafeev
-
Patent number: 10112911Abstract: This disclosure relates to: (a) compounds and salts of formula (I), formula (II), formula (III), and formula (IV), that, inter alia, inhibit RSV infection and/or replication; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions.Type: GrantFiled: June 28, 2013Date of Patent: October 30, 2018Assignee: ABBVIE INC.Inventors: Artour Gomtsian, Tatyana Dekhtyar, Kristine E. Frank, Michael M. Friedman, Nathan Josephsohn, M-Akhteruzzaman Molla, Anil Vasudevan, Iok Chan Ng, Mikhail Chafeev
-
Publication number: 20170360783Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 16 weeks, alternatively no more than 12 weeks, or alternatively no more than 8 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 16, 12, or 8 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: September 1, 2017Publication date: December 21, 2017Applicant: AbbVie Inc.Inventors: Christine Collins, Emily O. Dumas, Bo Fu, Abhishek Gulati, Yiran Bonnie Hu, Jens Kort, Matthew Kosloski, Preethi Krishnan, Yang Lei, Chih-Wei Lin, Ran Liu, Federico Mensa, Iok Chan Ng, Tami Pilot-Matias, David Pugatch, Susan Rhee, Nancy S. Shulman, Roger Trinh, Rolado M. Viani, Stanley Wang, Zhenzhen Zhang
-
Publication number: 20170333428Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: August 2, 2017Publication date: November 23, 2017Applicant: AbbVie Inc.Inventors: Christine Collins, Bo Fu, Abhishek Gulati, Jens Kort, Matthew Kosloski, Yang Lei, Chih-Wei Lin, Ran Liu, Federico Mensa, Iok Chan Ng, Tami Pilot-Matias, David Pugatch, Nancy S. Shulman, Rogert Trinh, Rolando M. Viani, Stanley Wang, Zhenzhen Zhang
-
Patent number: 9447051Abstract: This disclosure relates to: (a) compounds and salts thereof that, inter alia, inhibit RSV infection and/or replication; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions.Type: GrantFiled: February 15, 2013Date of Patent: September 20, 2016Assignee: AbbVie Inc.Inventors: Tatyana Dekhtyar, Arthur Gomtsyan, M-Akhteruzzaman Molla, Anil Vasudevan, Iok Chan Ng, Mikhail Chafeev
-
Publication number: 20160068521Abstract: This disclosure relates to: (a) compounds and salts thereof that, inter alia, inhibit RSV infection and/or replication; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions.Type: ApplicationFiled: April 22, 2014Publication date: March 10, 2016Inventors: Iok Chan Ng, M-akhteruzzaman Molla, Tami J. Pilot-Matias, Anil Vasudevan, Tatyana Dekhtyar, Artour Gomtsian, Katerina Sarris, Ana Aguirre, Mikhail Chafeev
-
Publication number: 20140080868Abstract: Pan-genotypic HCV inhibitors are described. This invention also relates to methods of using these inhibitors to treat HCV infection.Type: ApplicationFiled: September 17, 2013Publication date: March 20, 2014Applicant: ABBVIE INC.Inventors: Theresea (Iok-Chan) NG, Tami J. PILOT-MATIAS, Warren M. KATI, Preethi KRISHNAN, Clarence J. MARING, Neeta C. MISTRY, Thomas J. REISCH, Rolf WAGNER, Dachun LIU, John K. PRATT, Mark A. MATULENKO, Ryan G. KEDDY
-
Publication number: 20140080869Abstract: Pan-genotypic HCV inhibitors are described. This invention also relates to methods of using these inhibitors to treat HCV infection.Type: ApplicationFiled: September 17, 2013Publication date: March 20, 2014Applicant: ABBVIE INC.Inventors: Preethi KRISHNAN, Teresa (Iok-Chan) NG, Tami J. PILOT-MATIAS, Warren M. KATI, Clarence J. MARING, Neeta C. MISTRY, Thomas J. REISCH, Rolf WAGNER, Dachun LIU, John K. PRATT, Mark A. Matulenko, Ryan G. KEDDY
